Breaking News

RSSL Expands Subvisible Particle Analysis Service

Enables the firm to test according to USP

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Reading Scientific Services Ltd (RSSL) has introduced a new subvisible particle (SVP) test method for therapeutic protein, designed to cut the total volume of product required and reduce compliance costs.
 
The move enables the scientific consultancy to now test according to the procedures set out in USP Subvisible Particulate Matter in Therapeutic Protein Injections; a recently modified chapter which specifically addresses the unique sensitivities of protein formulations and high cost of sampling for compliance purposes.
 
“This new test method is a positive addition to our analytical capabilities; enabling us to offer pharmaceutical and biopharmaceutical manufacturers a cost-effective alternative to USP for therapeutic protein injectable and related liquid preparations,” said Yohanes Tamene, scientist, RSSL. “We  are now able to handle much smaller sample volume and test aliquots—as per the latest pharmacopeia regulation—to achieve significant cost savings for our clients, but without compromising any aspect of data validity, formulation quality or product safety.”
 
Under the requirements of USP , a combined volume of 25mL of pooled sample volume is required per single test to determine particulate counts. This compares to a total sample volume of just 1mL set out in the more recent USP which translates to a reduction of 96%. Given that quality testing must be carried out on every product batch, this saving represents a strong cost benefit for manufacturers of expensive protein-based therapeutic products.
  
“We know that when it comes to injectable and parenteral products, the presence of SVP can seriously compromise their safety, quality and efficacy,” sid Mr. Tamene. “It’s a challenging environment where any changes to product formulation, manufacturing process or exposure to stress conditions can prompt demands for additional sampling analysis. In addition, health authorities are also increasingly demanding SVP data which goes beyond that which is specified in the pharmacopeia.
 
“With this in mind, we felt it was vital to increase our capacity and offer customers the option of this additional service which is designed to balance compliance with commercial concerns.”
 
RSSL offers routine SVP testing to support batch release, as well as bespoke analysis to help during product development, reformulation and problem solving.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters